Crizotinib

Crizotinib Reactions 1680, p99 - 2 Dec 2017 ALK and KRAS mutations leading to acquired crizotinib resistance: 12 case reports In a study of 20 patients, 12 patients (eight women and four men) aged between 40–81 years were described, who developed anaplastic lymphoma kinase (ALK; n=5) and Kirsten rat sarcoma (KRAS; n=10) gene mutations leading to acquired crizotinib resistance [routes and dosages not stated]. The patients had a history of advanced ALK-positive non small cell lung cancer (NSCLC) and started receiving treatment with tyrosine kinase inhibitor (TKI), crizotinib. The patients experienced disease progression at different site like lymph node (n=3), brain (n=9), liver (n=2), lung (n=2) and pleura (n=2). Subsequent investigations revealed development of ALK and KRAS gene mutations which conferred the resistance. The patients started receiving treatment with chemotherapy (one patient), brigatinib (n=9) and ceritinib (one patient). The disease was stable in three of the 12 patients. Disease progression was observed in another three patients [not all outcomes stated]. Author comment: "To our knowledge, this is the first report to evaluate the acquired resistance to ALK-TKIs using cfDNA in a cohort of crizotinib-resistant NSCLC patients." Bordi P, et al. Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment. Clinical Lung Cancer 18: 692-697, No. 6, Nov 2017. Available from: URL: http://doi.org/10.1016/j.cllc.2017.04.013 - Italy 803284377 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Crizotinib

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/crizotinib-1GX0DhOrvw
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39030-8
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p99 - 2 Dec 2017 ALK and KRAS mutations leading to acquired crizotinib resistance: 12 case reports In a study of 20 patients, 12 patients (eight women and four men) aged between 40–81 years were described, who developed anaplastic lymphoma kinase (ALK; n=5) and Kirsten rat sarcoma (KRAS; n=10) gene mutations leading to acquired crizotinib resistance [routes and dosages not stated]. The patients had a history of advanced ALK-positive non small cell lung cancer (NSCLC) and started receiving treatment with tyrosine kinase inhibitor (TKI), crizotinib. The patients experienced disease progression at different site like lymph node (n=3), brain (n=9), liver (n=2), lung (n=2) and pleura (n=2). Subsequent investigations revealed development of ALK and KRAS gene mutations which conferred the resistance. The patients started receiving treatment with chemotherapy (one patient), brigatinib (n=9) and ceritinib (one patient). The disease was stable in three of the 12 patients. Disease progression was observed in another three patients [not all outcomes stated]. Author comment: "To our knowledge, this is the first report to evaluate the acquired resistance to ALK-TKIs using cfDNA in a cohort of crizotinib-resistant NSCLC patients." Bordi P, et al. Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment. Clinical Lung Cancer 18: 692-697, No. 6, Nov 2017. Available from: URL: http://doi.org/10.1016/j.cllc.2017.04.013 - Italy 803284377 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from Google Scholar, PubMed
Create lists to organize your research
Export lists, citations
Read DeepDyve articles
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off